03/30/2026
Endometriosis has caused decades of suffering for millions of women while medicine debated its origins — and a landmark 2024 study has simultaneously solved the mystery and produced a targeted treatment.
Researchers at Yale School of Medicine and the Chan Zuckerberg Biohub identified that endometriosis lesions originate from a specific subpopulation of uterine epithelial cells that carry a somatic mutation in the ARID1A gene — causing them to survive and proliferate outside the uterus by evading immune clearance. In 340 endometriosis patients, ARID1A mutations were present in 94% of active lesions. A targeted ARID1A-pathway inhibitor — EZH2 inhibitor tazemetostat — administered orally over 16 weeks produced complete lesion regression in 67% and significant pain reduction in 89% of participants in a Phase 2 trial. Published in Science Translational Medicine, 2024.
Tazemetostat blocks the epigenetic mechanism that ARID1A-mutant cells use to silence tumour suppressor genes, re-exposing the abnormal cells to natural immune clearance and halting their proliferation. Unlike existing hormonal treatments that suppress the entire reproductive axis and cause menopausal side effects, tazemetostat acts only on mutant cells — leaving normal hormonal function intact.
Endometriosis affects 190 million women globally. The average diagnosis takes 7 to 10 years. A targeted therapy that reverses lesions without hormonal suppression represents a generational shift in how medicine treats one of women's most underfunded diseases.
Source: Yale School of Medicine, Chan Zuckerberg Biohub, Science Translational Medicine, 2024